Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018–2025: A cross-sectional analysis
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116907 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Guanqiao Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vanke School of Public Health, Tsinghua University, Beijing, China; Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology an…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Approval, Clinical Trials, Phase III as Topic, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Arnold Ventures LLC, Alfonso Martín Escudero Foundation, Kaiser Permanente LLC.
Abstract (Originalsprache)
INTRODUCTION: Phase III randomised controlled trials often support FDA approval of new anticancer drugs, but trial quality reporting and clinical relevance vary. We assessed the risk of bias and clinical benefit of phase III randomised trials supporting FDA approvals of new anticancer drugs. MATERIALS AND METHODS: Cross-sectional study of pivotal phase III randomised trials supporting initial FDA approvals of anticancer drugs (January 1, 2018-May 15, 2025). Risk of bias was assessed using Cochrane Risk-of-Bias Tool 2.0 (low, some concerns, high), and clinical benefit with the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (substantial, intermediate, low). RESULTS: Among 43 indications supported by randomised trials, 21 (51%) were open-label. Overall survival benefit was demonstrated in 10 (23%) studies and quality of life improved in 6 (14%). Using a combined assessment incorporating publications and FDA regulatory documents, 13 trials (30%) were judged to be at low risk of bias, 24 (56%) raised some concerns, and 6 (14%) were at high risk of bias. Source-specific assessments differed: 19/42 trials (45%) were classified as high-risk based on published reports alone, versus 7/43 (17%) when assessed using FDA review documents alone. Substantial clinical benefit was observed in 14/43 (33%), but only 4 (9%) combined low risk of bias with substantial benefit. Among the 16 trials (37%) with low clinical benefit, 12 (75%) had methodological concerns or high risk of bias. Risk of bias was inconsistently associated with clinical benefit, overall survival, or quality-of-life outcomes. CONCLUSION: Recent FDA approvals of anticancer drugs frequently rely on trials with methodological limitations and limited clinical benefit. Integrating risk-of-bias and clinical benefit assessments may strengthen pre-approval evaluation and post-approval oversight, support patient communication, and inform value-based pricing decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanke School of Public Health, Tsinghua University, Beijing, China; Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospi…
- Vanke School of Public Health, Tsinghua University, Beijing, China.
- Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
- Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Elect…
Förderung
- Arnold Ventures LLC
- Alfonso Martín Escudero Foundation
- Kaiser Permanente LLC
Zitieren
APA
Li, G., Pu, Y., Chen, C., Kesselheim, A. S., & Tibau, A. (2026). Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018–2025: A cross-sectional analysis. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116907
Vancouver
Li G, Pu Y, Chen C, Kesselheim AS, Tibau A. Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018–2025: A cross-sectional analysis. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116907
BibTeX
@article{Li2026,
author = {Li, Guanqiao and Pu, Yiwen and Chen, Congzhou and Kesselheim, Aaron S and Tibau, Ariadna},
title = {Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018–2025: A cross-sectional analysis},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116907}
}
EUVIMED